Biologics In Inflammatory Bowel Disease, An Issue Of Gastroenterology Clinics Of North America

Hardcover | August 13, 2014

byEdward V. Loftus, JrEditorEdward V. Loftus, Jr

not yet rated|write a review

By the time this issue of Gastroenterology Clinics of North America is released, it will have been 16 years since infliximab was approved by the US Food and Drug Administration for the treatment of moderate to severe Crohn disease. Not only have we come a long way in understanding the efficacy and safety of infliximab, we are beginning to understand how and when to use the drug. Furthermore, as of this writing, we have five other biologic agents approved for either Crohn disease or ulcerative colitis, and there are many more molecules currently in drug development for these indications. In this issue,the Editors have assembled a collection of experts to provide the most cutting-edge information on the status of biologic therapy for inflammatory bowel disease.

Pricing and Purchase Info

$129.00

Ships within 1-2 weeks
Ships free on orders over $25

From the Publisher

By the time this issue of Gastroenterology Clinics of North America is released, it will have been 16 years since infliximab was approved by the US Food and Drug Administration for the treatment of moderate to severe Crohn disease. Not only have we come a long way in understanding the efficacy and safety of infliximab, we are beginning...

Format:HardcoverDimensions:9.41 × 7.24 × 0.98 inPublished:August 13, 2014Publisher:Elsevier CanadaLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:0323323251

ISBN - 13:9780323323253

Look for similar items by category:

Customer Reviews of Biologics In Inflammatory Bowel Disease, An Issue Of Gastroenterology Clinics Of North America

Reviews